We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue

New System Protects Healthcare Workers from Hazardous Drug Exposure

By HospiMedica International staff writers
Posted on 11 Aug 2015
Print article
Image: The Halo Closed System Transfer Device (CSTD) (Photo courtesy of Corvida Medical).
Image: The Halo Closed System Transfer Device (CSTD) (Photo courtesy of Corvida Medical).
A novel concept in hazardous drug protection provides health care professionals with a simple design that ensures compatibility with existing work procedures.

The Halo Closed System Transfer Device (CSTD) is an airtight, leak-proof, closed system that provides complete fluid and vapor containment and a strong vial attachment. Tests have shown the system prevents escape of hazardous drug or vapor concentration, bars the transfer of environmental contaminants, and prevents microbial ingress. The easy to use system comes with few pieces and fewer steps, and is compatible with existing work procedures, protocols, and disposable equipment.

The system mechanically prohibits the transfer of environmental contaminants into the system, and the escape of drug or vapor concentrations outside the system. This is achieved by addressing safety concerns for each connection type, such as drug vial adapters, syringe and line adapters, and bag spikes, containing the drug through each of the reconstitution and transfer steps. The Halo CSTD is a product of Corvida Medical (Coralville, IA, USA), and has been approved by the US Food and Drug Administration (FDA).

“We are focused on developing and introducing products designed to meet critical unmet needs, and have worked closely with thought leaders throughout our product development efforts. The feedback on Halo has been phenomenal,” said Kent Smith, President and CEO of Corvida Medical. “Health care professionals appreciate Halo’s simplicity and we look forward to introducing it to the market.”

Healthcare workers are continuously exposed to hazardous drugs during the preparation and delivery of chemotherapy, which can cause serious health problems, including cancer, infertility, genetic mutations, and other adverse effects. Protective equipment intended to shield from these dangers often can be complicated, difficult to use, and provide incomplete solutions.

Related Links:

Corvida Medical

Print article



view channel

Hillrom Acquires Bardy Diagnostics to Expand into Ambulatory Cardiac Monitoring Segment

Hillrom (Chicago, IL, USA) has reached a definitive agreement to acquire Bardy Diagnostics, Inc. (BardyDx; Seattle, WA, USA) for a cash consideration of USD 375 million. The acquisition of BardyDx,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.